HealthcareServices

Global Chronic Plaque Psoriasis Market Report 2026: Emerging Trends and Growth Scenarios

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic plaque psoriasis market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Chronic Plaque Psoriasis Market by the end of 2030?

The market for chronic plaque psoriasis has experienced significant expansion recently. It is projected to increase from $22.26 billion in 2025 to $23.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.1%. Historically, this growth has been driven by factors such as enhanced diagnosis of autoimmune skin conditions, broader access to topical treatments, heightened public awareness concerning psoriasis management, the proliferation of dermatology clinics, and better availability of specialized medications.

The chronic plaque psoriasis market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a value of $30.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This projected growth is driven by several factors, including the escalating development of advanced biologics, the increasing embrace of oral immunomodulators, the broader application of precision dermatology, a heightened emphasis on patient-centered care strategies, and boosted investments in autoimmune disease research. Key trends anticipated during this period involve the rising acceptance of biologic therapies, the increased utilization of targeted small molecule medications, a sharpened focus on individualized dermatological care, the proliferation of oral treatment alternatives, and a greater commitment to sustained disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

What Drivers Are Shaping Future Opportunities In The Chronic Plaque Psoriasis Market?

The future expansion of the chronic plaque psoriasis market is anticipated to be driven by the rising incidence of immune system dysfunction. This dysfunction describes a condition where the immune system fails to function properly, making individuals more vulnerable to infections, autoimmune disorders, and cancer. Various elements, including genetic factors, environmental influences, poor nutrition, ongoing stress, and the growing occurrence of autoimmune conditions and infections such as HIV, contribute to the increasing instances of immune system dysfunction. Treatment for chronic plaque psoriasis is essential for managing immune system dysfunction, given that the immune system erroneously stimulates excessive skin cell production, resulting in inflammation and plaque formation. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that in 2025, approximately 212,136 males and 362,137 females are forecast to develop rheumatoid arthritis (RA). These figures are projected to increase by 2040, reaching an estimated 280,040 males and 479,828 females. Consequently, the expanding number of immune system dysfunction cases is propelling the growth of the chronic plaque psoriasis market.

Which Segment Groups Are Influencing The Chronic Plaque Psoriasis Market?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

What Trends Are Driving The Growth Trajectory Of The Chronic Plaque Psoriasis Market?

Major companies within the chronic plaque psoriasis market are concentrating on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to advance the therapeutic landscape for chronic plaque psoriasis. These IL-17A and IL-17F inhibitors function as targeted biologic therapies, blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, to diminish inflammation in autoimmune disorders like chronic plaque psoriasis. For example, in October 2023, UCB S.A., a biopharmaceutical company based in Belgium, announced that the U.S. Food and Drug Administration (FDA) had granted approval for BIMZELX (bimekizumab-bkzx) for use in adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Bimekizumab is notable as the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two significant cytokines implicated in inflammatory processes. Its approval was substantiated by evidence from three Phase 3 multicenter trials — BE READY, BE VIVID, and BE SURE — which collectively assessed its safety and efficacy in 1,480 patients suffering from moderate to severe plaque psoriasis.

Who Are The Prominent Global Companies Shaping The Chronic Plaque Psoriasis Market Landscape?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Region Currently Holds The Largest Share Of The Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Plaque Psoriasis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

Rheumatology Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Chronic Spontaneous Urticaria Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Veterinary Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795